Clinical trials: Mosquito-Borne Diseases
Malaria
Safety of KAE609 in Adults With Uncomplicated Plasmodium Falciparum Malaria.
KAE609 will be evaluated primarily for hepatic safety of single and multiple doses in sequential cohorts with increasing doses.This study aims to determine the maximum safe dose of the investigational drug KAE609 in malaria…
- Trial name
- NCT03334747
- Testing
- KAE609, Coartem
- Where
- 9 sites in Gabon, Ghana and 3 more
- Volunteers
- 188 people
- Sponsor
- Novartis Pharmaceuticals
Plasmodium Falciparum Malaria
Safety and Preliminary Protective Efficacy of Genetically Attenuated GA2 Parasites.
This study will consist of two phases and be aimed at assessing the safety and tolerability of the new genetically attenuated GA2 malaria parasite (Phase 1) and its preliminary protective efficacy against controlled human malaria…
- Trial name
- NCT04577066
- Testing
- GA2, GA1
- Where
- Netherlands
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Leiden University Medical Center
Malaria, Pregnancy
Impact of IPT With Sulfadoxin Pyrimetamin on Pregnant Women and Their Babies Outcomes in Peri-urban Areas of Bobo-Dioulasso(Burkina Faso)
The purpose of this is to determine the impact of intermittent preventive treatment (IPT) with sulfadoxine-pyrimethamine (SP) on the morbidities associated with malaria in pregnant women and newborns in rural peri-urban areas of…
- Trial name
- NCT01255605
- Where
- Burkina Faso
- Volunteers
- 772 people
- Sponsor
- Université Polytechnique de Bobo-Dioulasso
Malaria
Evaluating ATSBs for Malaria Reduction in Kenya
The effectiveness of long-lasting insecticidal nets (LLINs) and indoor residual spraying (IRS) in western Kenya are threatened by insecticide resistance and vector behaviour changes toward early evening and outdoor biting malaria…
- Trial name
- NCT05219565
- Testing
- Attractive Targeted Sugar Bait (ATSB)
- Where
- 9 sites in Kenya
- Volunteers
- 2,962 people, healthy volunteers welcome
- Sponsor
- Liverpool School of Tropical Medicine
Lymphatic Filariases, Onchocerciasis
Prevalence of LF Infection in Districts Not Included in LF Control Activities
Lymphatic filariasis is a neglected tropical disease earmarked for elimination as a public health problem by the year 2020. Since the year 2000, the Global Program for the Elimination of LF has together with endemic countries…
- Trial name
- NCT03131401
- Testing
- Diagnosis of lymphatic filariasis, Diagnosis of lymphatic Filariasis and onchocerciasis, DEC Patch
- Where
- Ghana
- Volunteers
- 3,736 people
- Sponsor
- Noguchi Memorial Institute for Medical Research
Dengue, Pregnancy
Study on the Risks of Symptomatic Dengue on Pregnancy
Dengue fever is the most common arbovirus worldwide (390 million people infected per year) and is a global public health problem.
- Trial name
- ERiDenG (NCT04826081)
- Testing
- data collection
- Where
- France
- Volunteers
- 336 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de la Réunion
Chikungunya
Study of a Live Attenuated Chikungunya Vaccine in a Previously Epidemic Area
The clinical study primarily assesses the safety of MV-CHIK a new Chikungunya vaccine in a previously epidemic area in healthy volunteers. Secondarily, immune response and viremia will be assessed.
- Trial name
- NCT03101111
- Testing
- MV-CHIK, MMR-vaccine
- Where
- Puerto Rico
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Themis Bioscience GmbH
Malaria
GMZ2-Aluminum Hydroxide Phase I, Tübingen
This is a randomized, open, dose-selection Phase 1 study. The study aims to evaluate the safety and immunogenicity of 3 doses (10,30 \& 100 micrograms) of the GMZ2 hybrid (GLURP and MSP3) blood stage vaccine in healthy non-immune…
- Trial name
- NCT00397449
- Testing
- GMZ2 (GLURP + MSP3 Hybrid) (malaria vaccine)
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- European Vaccine Initiative
Malaria, Sexually Transmitted Diseases
Gestational Sulfadoxine-pyrimethamine and Azithromycin Treatment to Prevent Preterm Birth
The purpose of this study is to examine whether treatment of pregnant Malawian women with repeated doses of sulfadoxine-pyrimethamine and azithromycin antibiotics will prevent preterm deliveries and result in other health…
- Conditions
- Malaria, Sexually Transmitted Diseases, Preterm Birth, Pregnancy
- Trial name
- NCT00131235
- Testing
- Sulfadoxine-pyrimethamine treatment twice during pregnancy, Sulfadoxine-pyrimethamine at 4-week intervals, Sulfadoxine-pyrimethamine every 4 weeks + azithromycin twice
- Where
- Malawi
- Volunteers
- 1,320 people, healthy volunteers welcome
- Sponsor
- Tampere University
Malaria, Pneumonia
Home Management of Malaria and Pneumonia
A well-implemented community-based program of early and appropriate treatment of fevers/malaria episodes and pneumonia,will improve child survival as measured by a reduction of the less than five mortality rate.
- Trial name
- HMM/P (NCT02151578)
- Testing
- home/community case management
- Where
- Burkina Faso
- Volunteers
- 11,500 people
- Sponsor
- World Health Organization
Malaria, Low Birth Weight
Malaria in Pregnancy: Nutrition and Immunologic Effects
The purpose of this study is to determine the efficacy of zinc and/or vitamin A supplementation in reducing the risk of placental malaria and its associated adverse pregnancy outcomes.
- Conditions
- Malaria, Low Birth Weight, Anemia, Perinatal Mortality
- Trial name
- MAL2 (NCT01115478)
- Testing
- Vitamin A, Zinc
- Where
- Tanzania
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Harvard School of Public Health (HSPH)
Zika Virus, Zika Virus Infection
Randomized, Placebo-controlled, Observer-blinded Phase 1 Safety and Immunogenicity Study of Inactivated Zika Virus Vaccine Candidate in Healthy Adults
In this Phase 1 study, two target dose levels of VLA1601, a purified, inactivated, whole Zika virus (ZIKV) vaccine candidate adsorbed on aluminum hydroxide (alum) will be evaluated: 6 antigen units (AU) and 3 AU of inactivated…
- Trial name
- NCT03425149
- Testing
- VLA1601
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Zika Virus Infection
A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.
Phase 1 study to evaluate two doses of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) administered 28 days apart. The study will enroll 75 flavivirus naïve healthy adult subjects into 3 equal groups sequentially.
- Trial name
- NCT02963909
- Testing
- IXIARO, YF Vax 17D Strain, Zika Virus Purified Inactivated Vaccine (ZPIV)
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria, HIV
Dolutegravir Interactions With Artemisinin-based Combination Therapies
Malaria and HIV are found in the same regions of the world and developing countries are most affected by both diseases. For malaria, new drugs have been introduced called ACTs.
- Trial name
- DolACT (NCT02242799)
- Testing
- Dolutegravir 50mg od, Artemether-lumefantrine combination, Artesunate-amodiaquine
- Where
- Uganda
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- University of Liverpool
Malaria
Community Access to Rectal Artesunate for Malaria
Many malaria deaths occur in places where people have poor access to preventive and curative health services. Prompt access to quality health services is critical in the case of severe childhood diseases, among which severe…
- Trial name
- CARAMAL (NCT03568344)
- Where
- 3 sites in Democratic Republic of the Congo, Nigeria and 1 more
- Volunteers
- 13,758 people
- Sponsor
- Swiss Tropical & Public Health Institute
Malaria,Falciparum
Addressing Asymptomatic Plasmodium Reservoirs to Accelerate Malaria Elimination and Eradication in Rwanda.
The investigators believe that to effectively achieve malaria elimination in Rwanda, it is critical to target the human reservoirs of Plasmodium falciparum using local and readily available Artemisia tea.
- Trial name
- NCT05801198
- Testing
- Artemisia afra or Annua 10g oral infusion/tea per day for 14 days
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- King Faisal Hospital Rwanda
Dengue
Demographic Characteristics of TAK-003 Dengue Vaccine Recipients in Vietnam
The study aims to retrospectively describe the demographic characteristics, comorbidity profiles, vaccination history and vaccination patterns of all individuals who have received at least one dose of TAK-003 (Qdenga) dengue…
- Trial name
- TAK-003 (NCT07501793)
- Where
- Vietnam
- Volunteers
- 800,000 people, healthy volunteers welcome
- Sponsor
- Tam Anh Research Institute
Malaria, Falciparum, G6PD Deficiency
Safety and Tolerability of Low Dose Primaquine
In Cambodia, falciparum is becoming more difficult to treat because drugs are becoming less effective. The investigators can help to try to prevent the spread of this resistant malaria by adding a drug that will make it more…
- Trial name
- NCT02434952
- Testing
- Dihydroartemisinin piperaquine (DHA PP), Primaquine
- Where
- Cambodia
- Volunteers
- 109 people
- Sponsor
- Malaria Consortium
Malaria
A Study to Find the Minimum Inhibitory Concentration of KAE609 in Adult Male Patients With P. Falciparum Monoinfection
This study aims to determine the Minimum Inhibitory Concentration of KAE609 in adult male patients with acute, uncomplicated malaria due to P.falciparum monoinfection after single dosing with KAE609
- Trial name
- NCT01836458
- Testing
- KAE609
- Where
- Vietnam
- Volunteers
- 25 people
- Sponsor
- Novartis Pharmaceuticals
Malaria
A Phase I Study to Assess the Safety and Immunogenicity of ChAd63 ME-TRAP - MVA ME-TRAP Heterologous Prime-boost Vaccination Co-administered With EPI Vaccines in Gambian Infants
Two vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, are being tested to see if they will form a safe and effective vaccination strategy against malaria.
- Trial name
- VAC058 (NCT02083887)
- Testing
- ChAd63 ME-TRAP / MVA ME-TRAP
- Where
- The Gambia
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- University of Oxford